LAUSR

Immunotherapy of tumor attracts great attention in the past several years attributing to the potential of completely erasing primary tumor and metastasis. Therefore, pharmaceutical companies developed many antibodies that act as immune check point blockade (ICB), such as Nivolumab, Atezolizumab and Ipilimumab. However, the antitumor immune response in clinic is relatively low because of the immunosuppressive conditions in the tumor sites. To improve the immunotherapy, many strategies are developed to stimulate the immune response and relieve the immunosuppressive microenvironment [1] . Photothermal therapy, photodynamic therapy and several chemotherapeutics are demonstrated with the ability of inducing immunogenic cell death (ICD), which show promising synergic effect with ICB. For tumor photoimmunotherapy, ICD and cytotoxicity effects can only be produced after laser irradiation, which can avoid the side effects of non-target organs brought by chemotherapy. Therefore, there is a trend in the tumor immunotherapy of developing photo-immunotherapy combinational strategies.